Pharmacologic characteristics of statins
- 1 April 2003
- journal article
- review article
- Published by Wiley in Clinical Cardiology
- Vol. 26 (S3) , 32-38
- https://doi.org/10.1002/clc.4960261507
Abstract
Considerable effort has been devoted to improving the pharmacologic characteristics and clinical effects of statins. Desirable pharmacologic properties include potent inhibition of hydroxymethylglutaryl coenzyme A (HMG‐CoA) reductase, selectivity of uptake in hepatocytes, low systemic bioavailability to reduce systemic adverse effects, prolonged elimination half‐life, and no or minimal hepatic metabolism to avoid drug‐drug interactions. The desirable effects on lipid variables would include increased effectiveness in reducing levels of low‐density lipoprotein cholesterol and other atherogenic lipoproteins and measurable beneficial effects on high‐density lipoprotein cholesterol levels. As a product of the ongoing efforts regarding statin pharmacology, the new statin rosuvastatin exhibits significant improvements in several of these characteristics.Keywords
This publication has 24 references indexed in Scilit:
- Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemiaAmerican Heart Journal, 2002
- Optimizing the pharmacology of statins: characteristics of rosuvastatinAtherosclerosis Supplements, 2002
- Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemiaPublished by Elsevier ,2002
- Rosuvastatin Demonstrates Greater Reduction of Low-Density Lipoprotein Cholesterol Compared with Pravastatin and Simvastatin in Hypercholesterolaemic Patients: A Randomized, Double-Blind StudyEuropean Journal of Preventive Cardiology, 2001
- Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levelsThe American Journal of Cardiology, 2001
- Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemiaThe American Journal of Cardiology, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Structural Mechanism for Statin Inhibition of HMG-CoA ReductaseScience, 2001
- Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.The American Journal of Cardiology, 2001
- Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cellsAtherosclerosis, 2000